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Albumin synthesis, albuminuria and hyperlipemia in nephrotic pa.
tients. Hyperlipemia is a common manifestation of the nephrotic
syndrome. Serum lipid concentrations have been observed by others to
be negatively correlated with serum protein concentration. Hyper-
lipemia has been postulated to result from a coordinate increase in the
synthesis of both albumin and lipoproteins, as well as from their
decreased catabolism. Simultaneous measurements of serum lipid con-
centration and the rate of albumin synthesis have not been previously
reported. We measured the rate of albumin synthesis, urinary albumin
loss, serum albumin, protein, cholesterol and triglyceride concentration
in 13 nephrotic patients. Changes in the rate of albumin synthesis and in
urinary albumin excretion were induced in eight patients by alteration in
dietary protein intake. The resultant changes in serum triglyceride and
cholesterol were analyzed by multiple regression analysis. The rate of
albumin synthesis measured while patients were eating a low protein
diet was 12.61 1.20 gIl .73 m2/day, well within normal limits, yet both
serum triglyceride and cholesterol concentrations were markedly ele-
vated (265 65 mgldl and 325 44 mg/dl, respectively). Albumin
synthetic rate increased to 17.60 1.25 gIl .73 m2/day when dietary
protein intake was increased, while serum triglyceride and cholesterol
concentrations changed little; triglyceride concentration was 306 75
mg/dl and cholesterol 376 55 mgldl. Serum cholesterol concentration,
by multiple regression analysis, was dependent only upon the renal
clearance of albumin P < 0.0001, and changes in serum cholesterol
concentration was dependent only upon changes in the renal clearance
of albumin, P <0.001. Serum cholesterol concentration was completely
independent of the rate of albumin synthesis. Serum triglyceride
concentration was also primarily dependent upon the renal clearance of
albumin, r2 = 0.663 P < 0.0001, with some contribution by the rate of
albumin synthesis, r2 = 0.112, P = 0.028. Changes in serum triglyceride
concentration were also dependent upon changes in the rate of albumin
synthesis, r2 = 0.624, P < 0.002. We could find no evidence for a
relationship between hypercholesterolemia and the rate of albumin
synthesis in nephrosis. While serum triglyceride concentration showed
some correlation with the rate of albumin synthesis, the very fact that
the rate of albumin synthesis was only modestly increased, if at all,
while serum triglyceride concentration was grossly elevated, made it
unlikely that there was a direct link between albumin synthesis and that
of either triglycerides or of apolipoproteins. These data suggest that the
renal loss of macromolecules, either albumin, or other substances
cleared by the kidney in a parallel fashion with albumin, play a role in
the deranged cholesterol metabolism in nephrosis, and perhaps also
contribute to derangements in triglyceride metabolism in these patients
as well.
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Hyperlipidemia is, in conjunction with albuminuria, and
hypoalbuminemia, a characteristic of the nephrotic syndrome
[1, 21. The mechanism for its occurrence is complex and
involves a combination of reduced clearance of lipoproteins
from the circulation [2—6] and increased hepatic synthesis of
lipoproteins [3, 4, 7—9]. Most investigators have found a nega-
tive correlation between serum albumin concentration and
serum cholesterol levels [3, 4, 10, 11], but serum triglyceride
levels have been less clearly related to serum protein concen-
tration.
Plasma lipid concentrations can be reduced by infusion of
albumin or other macromolecules capable of increasing serum
oncotic pressure [12, 13]. One interpretation of these data is
that increased oncotic pressure leads to a reduction in the rate
of albumin synthesis [13, 14]. It is postulated that the increased
rate of albumin synthesis that might occur in nephrosis might
cause a parallel increase in the rate of synthesis of all hepatic
secretory proteins [7, 14, 15]. Reduction in the rate of albumin
synthesis postulated to occur after the infusion of oncotically
active macromolecules would then lead to the parallel reduction
in the rate of synthesis of lipoproteins. Albumin synthesis rates
were not measured during these studies, however.
A potential relationship between the oncotic pressure of a
putative intrahepatic interstitial pooi of albumin and the rate of
albumin synthesis has been identified [16, 17], but no clear
relationship between the oncotic pressure of this pooi and
serum oncotic pressure is discernable. It is difficult, therefore,
to predict the rate of albumin synthesis from measurements of
serum oncotic pressure.
Albumin homeostasis in nephrosis is complex. Multiple ob-
servers have been unable to demonstrate a correlation between
serum albumin concentration and the rate of albumin synthesis
[16—18], nor is there evidence that reduction in serum albumin
concentration acts as a direct stimulus to albumin synthesis.
Albumin may even be synthesized at subnormal rates in some
nephrotic patients [16]. In order to draw inferences between the
rate of albumin synthesis and plasma or serum lipid concentra-
tions in this syndrome, it is necessary to actually measure the
rate of albumin synthesis, or steady state turnover. Since it is
difficult to infer causality from linear correlation alone, it would
be useful to alter the rate of albumin synthesis in some way and
determine the effect of that change on serum lipid concentra-
tion. To ascertain the relationship, if any, between the rate of
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albumin synthesis and serum triglycerides and cholesterol con-
centrations, albumin turnover at steady state was measured in
thirteen patients with the nephrotic syndrome. When nephrotic
patients [19] or rats [20] are fed a low protein diet, the rate of
albumin synthesis is reduced. Therefore, paired studies were
performed in eight of these patients to determine whether
changes in the measured rate of albumin synthesis, urinary
albumin excretion and serum albumin concentration that oc-
curred subsequent to changes in the protein content of their diet
might affect the serum concentration of cholesterol or triglyc-
erides.
Methods
Patients with proteinuria greater than 3.5 g/24 hr measured in
the renal clinic prior to admission were asked to participate in
this study. Informed consent was obtained from each patient.
All patients had known proteinura for at least six months prior
to this study. Renal biopsy was performed prior to the study in
nine of the patients. Diabetic renal disease was diagnosed
clinically in patients 2, 4 and 7 without renal biopsy. No
diagnosis was available for patient 13. The patients ranged in
age from 20 to 78 years. Further clinical information is pre-
sented in Table 1.
All patients were studied while on a fixed diet. Patients 1
through 3 were interviewed by a dietitian. A nutritional history
was obtained, and the patients were each placed on a constant
diet containing a content of protein, carbohydrate and lipid
comparable to what they were eating prior to admission. Patient
4 was on constant total parenteral nutrition prior to and during
the study. Patients 6 through 13 were studied in a paired
fashion. Patients 6 through 11 were placed on a fixed diet
containing 1.6 grams of protein and 35 kcal while patients 12
and 13 were placed on an isocaloric diet containing only 0.8 g of
protein per kilogram body weight. The diets were comparable in
lipid composition and in the content of sodium, calcium and
phosphorus. Carbohydrate was substituted for protein in the
preparation of the low protein diet. Patient 5 received only the
1.6 g/kg protein diet.
All patients remained on the selected diet for a minimum of
two days prior to study of albumin metabolism. The patients
then received 10 drops of Lugol's solution twelve hours and one
hour before injection of 125j albumin to block thyroid uptake of
1251.1251 albumin (Mallinkrodt, Inc. St. Louis, Missouri, USA)
10 DCi, was injected into a peripheral vein. Blood samples (3
ml) were obtained from a peripheral vein at 5, 15, minutes and
at 1, 2, 5, and 10 hours after injection. Additional samples were
drawn 24 hours after the injection and daily for two weeks.
Urine was collected daily. Following the first study of albumin
turnover, dietary composition was altered. Patients 6 through
11 were placed on the 0.8 gram protein per kilogram body
weight diet, and patients 12 through 14 were given the 1.6 gram
protein per kilogram body weight diet. The second diet was
maintained for a five to fourteen day equilibration period. A
second 10 Ci dose of 1251 albumin was administered, and
albumin turnover was measured during the subsequent 14 days
in an identical fashion as during the first dietary period.
Creatinine clearance was measured in all patients but number
I. Each value represents the mean of 14 consecutive measure-
ments. In the nine patients in whom paired studies were
performed each value of creatinine clearance (Table 1) repre-
sents the mean value obtained during the particular measure-
ment of albumin metabolism.
Several patients were receiving medications: diuretics or
antihypertensive agents to control blood pressure or edema,
digoxin, and one patient was receiving prednisone. The specific
drugs that each patient was taking are referred to in Table 1.
Drug dosages were, wherever possible, not altered during the
course of study.
Measurement of albumin synthesis and catabolism
If serum was lactescent, it was centrifuged at 126000g for 10
minutes in a microultracentrifuge (Beckman, Palo Alto, Cali-
fornia, USA). The clear infranate was used for determination of
radioactivity and for chemical measurements. One ml of each
serum sample was counted in a Packard 3002 gamma counter
for three 10 minute periods and the results averaged. The
counting efficiency was 76%, the standard error of counting was
less than 1%. One ml urine aliquots were precipitated with 10%
trichloracetic acid (TCA). The samples were centrifuged in a
Beckman microfuge (Beckman) for five minutes, the supernate
decanted and used to determine the fraction of nonprecipitable
1251. The pellet was dissolved in 1% sodium hydroxide and
reprecipitated. The resulting pellet was dissolved in a total
volume of 1 ml of 1% sodium hydroxide. The TCA supernatant
and the dissolved pellet were each counted for three 10 minute
periods in a Packard 3002 gamma counter. Urine samples were
analyzed in triplicate.
Total albumin turnover was measured by a pharmacokinetic
method, integrating the plasma radioactivity curve [21, 22]. The
dose of 1251 albumin injected (D), divided by the integral of the
plasma radioactivity curve (AUC) is a clearance term:
D
AUC
The product of this term and the serum albumin concentration
is then total albumin loss by all routes [23]. Under steady state
conditions,
D
x serum albumin concentration =
AUC
total albumin turnover.
This value is also equal to the average rate of albumin synthesis
during the period studied. Plasma volume is calculated by
isostope dilution [23] using 1251 values. Plasma albumin mass
(PAM) is equal to the product of plasma volume and serum
albumin concentration. Steady state volume of distribution
(Vdss) was measured by the non-compartmental method of
Benet and Galeazzi [211. Total albumin mass (TAM) is the
product of the serum albumin concentration and the apparent
volume of distribution of albumin.
TAM = serum albumin concentration x Vdss
Extravascular albumin mass (EVAM) is TAM minus PAM.
Albumin turnover measured by this method will equal the
albumin synthesis rate if patients are in steady state, that is, if
serum albumin concentration and urinary albumin excretion
rates remain constant. Since body weight, urinary albumin
excretion and serum albumin concentration did not vary signif-
icantly throughout these studies, steady state criteria were met.
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I, furosemide; 2,
Albumin catabolic rate was measured by the method of Gitlin
and Janeway [241. Urine was collected until the excretion rate
of 1251 was negligible. The average specific radioactivity of
urinary albumin was determined, and total urinary nonprotein
bound 1251 was measured as well. Albumin catabolic rate is
then:
Urinary nonprotein 1251 (total)Albumin cataboloic rate =
specifiè radioactivity of x
(total time) urinary albumin
This method is based on the observation that the specific
radioactivity of urinary albumin is equal to the specific radio-
activity of serum albumin at any given time, and the iodine
released from catabolism of i25J labeled albumin all appears in
the urine as TCA soluble 1251. The method is dependent on a
constant relationship between albuminuria and albumin cata-
bolic rate throughout the experimental period, but is unaffected
by variations in albuminuria or by delay in iodine excretion.
Measurement ofserum and urine protein
Albumin was measured both in serum and urine by electro-
immunodiffusion [251. Total protein was measured by the
method of Bradford using an albumin standard [261. Values for
serum albumin and protein concentrations, and for urinary
protein and albumin excretion rates represent the average of 14
daily consecutive measurements. Serum colloid osmotic pres-
sure (COP) was calculated by the method of Nitta et al [27) for
serum with albumin/globulin ratios different than one.
Renal albumin clearance during each experimental period
was calculated using the mean urinary albumin excretion per 24
hours and mean serum albumin concentration.
Measurement of blood lipids
Serum samples were obtained during fasting once on day 10
of each dietary period, and were extracted with chloroform:
methanol (2: 1). Salicic acid was added to the chloroform phase
to remove phospholipids [281. An aliquot containing 30 to 100 g
of triglyceride was evaporated to dryness and redissolved in
isopropanol for colorimetric determination according to the
method of Fletcher [291. Total cholesterol was determined with
a cholesterol oxidase kit (Sigma Kit No. 350-B).
Statistics
Data analysis were by multiple regression analysis using a
National Institutes of Health computer research—resource de-
veloped specifically for use by biomedical scientists—
PROPHET [30]. The program used generates a table of partial
correlation coefficients and then analyzes these by a "stepwise
regression procedure" [30]. Independent variables are added to
or removed from the equation depending upon their contribu-
tion to the overall fit of the model. The addition of any variable
will increase the overall r2 of the multiple correlation. The
program therefore only adds variables that increase the signif-
icance of the overall multiple regression at each step. Variables
that do not increase the significance of the overall regression are
not added to the model. Following each interaction, the residual
Table 1. Clinical characteristics, parameters of albumin homeostasis and dietary intake of patients studied
Weight Surface
Creatinine
clearance Calorie Protein
Serum
cholesterol
Patient Sex Age kg area m2 Diagnosis Medicationsa mI/mm Intake/kg mg/d!
I. M 39 55.5 1.65 Membrano proliferative
glomerulo nephritis
None NA 31.6 1.50 474
2. F 64 75.5 1.72 Diabetes mellitus 1,8 20.5 22.6 0.84 261
3. M 20 79 1.82 Focal glomerulo-
nephritis
None 103.6 39 1.44 207
4. F 35 51 1.50 Diabetes mellitus 1,8 33.7 33 1.20 330
5. M 30 70.5 1.95 Focal glomerulo-
sclerosis
1 50.4 35 1.60 435
6. M 39 102 2.35 Focal glomerulo-
sclerosis
1,4,5,13 48.1
41.6
35 1.60
35 0.80
876
538
7. M 70 112 2.29 Diabetes mellitus 1,7,8,10,14 48.4
48.5
35 1.60
35 0.80
133
166
8. M 64 88 2.04 Membranous
nephropathy
1,6,9 72.5
68.8
35 1.60
35 0.80
328
236
9. M 49 68 1,85 Amyloidosis 3 26.8
20.1
35 1.60
35 0.80
390
390
10. M 74 81 2.07 Membrano proliferative
glomerulonephritis
1,10,11 52.1
49.4
35 1.60
35 0.80
198
168
11. F 78 60 1.61 Membranous
nephropathy
1,4 85.5
92.5
35 1.60
35 0.80
326
303
12. M 67 101 2.23 Membranous
nephropathy
1,4,15 46.6
48.4
35 1.60
35 0.80
378
390
13. M 69 60 1.61 Unknown (solitary
functioning kidney)
2,4,5 21.5
20.2
35 1.60
35 0.80
442
478
a Medications that patients were taking during the course of the study are indicated numerically: bumetanide; 3,
hydrochlorothiazide; 4, metolazone; 5, amiloride; 6, prazosin; 7, hydralazine; 8, insulin; 9, tolbutamide; 10, digoxin; 11, isosorbide dinitrate; 12,
coumadin; 13, prednisone; 14, allopurinol; 15, ferrous sulfate.
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Table 1. Continued
Serum
tn-
glyc-
endes
mg/dl
Serum
albumin
concen-
tration
gIdI
Serum
protein
concen-
tration
g/dl
Serum
oncotic
pressure
Torr.
Urinary Urinary
albumin protein
excretion excretion
Renal
albumin
clearance
pJlmin
Albumin Albumin
synthesis catabolic
rate rate
Total
albumin
mass
Plasma
albumin
mass
Extra
vascular
albumin
mass
g/l.73 m2124 hr gIl.73 ,n/24 hr g/!.73 in2
ND 2.71 4.75 13.8 5.10 9.59 124 15.05 11.2 112 51 61
406
197
3.55
3.3
6.32
6.96
20.7
22.4
2.10 3.02
1.67 2.30
41
35
7.83 6.5
11.7 8.32
I54
68
66
80.4
88
149
ND
344
2.19
1.32
3.47
3.99
9.56
8.75
3.68 5.40
17.1 23.9
101
1015
16.4 12.7
27 5.8
140
65.6
70
29.8
70
35.8
798
554
113
123
347
124
129
149
53
55
211
lOS
335
340
422
532
0.83
0.81
2.60
2.87
2.70
2.77
1.77
2.10
3.22
3.66
2.58
2.69
1.30
1.67
0.72
0.90
3.55
3.25
4.45
5.20
4.00
4.10
3.86
3.56
5.38
7.31
5.30
6.56
3.44
3.67
3.8
5.2
6.72
6.10
12.8
15.5
11.9
12.3
9.48
9.56
16.8
24.7
15.0
19.3
7.54
8.84
6.99
10.7
16.9 25.0
9.5 14.8
5.7 9.5
5.6 8.7
8.2 10.4
1.8 2.7
5.0 7.7
4.6 7.1
8.5 13.5
5.9 6.1
7.8 8.9
5.9 7.1
9.5 11.1
5.9 7.7
7.5 12.3
7.1 11.6
1916
1106
201
179
249
52
210
161
220
134
195
143
499
256
652
506
24.2 6.8
17.8 4.7
16.5 9.1
15.4 9.0
19.05 11.6
9.3 3.9
18.4 10.6
16.3 11.9
18.1 10.8
12.5 5.9
15.7 11.5
10.0 8.2
16.1 6.6
9.58 5.6
13.0 4.4
14.8 3.8
47.9
56.5
214
282
148
126
128
100
201
215
100
100
107
81
40
68
23.8
22.8
88
106
76
85
59
62
116
130
56
63
48
51
21
32
24.1
33.7
126
176
72
41
69
38
85
85
45
37
59
30
19
36
contribution of each of the variables to the fianal model are
recomputed. Since several of the dependent variables are
dependent upon one another (serum protein concentration and
colloid osmotic pressure, for example), their partial correlation
coefficient will be reduced with each subsequent iteration. The
initial tables of partial correlation coefficients are therefore not
presented in the results section, inasmuch as they are not
directly interpretable. The results of simple linear regression
analysis also do not contribute to the development of a model
describing the relationship between the dependent variable and
the multiple independent variables tested. The results of several
linear regression analyses are presented, however, in graphic
form to provide visual analysis of the relationships between
several of the variables analyzed. No conclusions were drawn,
however, from simple linear regression analysis. Measurement
of serum triglyceride was not performed in two patients (Nos. I
and 4). Data from these patients were, therefore, not used in the
multivariant analysis to evaluate plasma triglycerides. Two
measurements of each parameter were available on patients 6
through 13—one measurement on each diet. The set of data for
each dietary period was evaluated for each patient as a separate
entry. Two data points are therefore entered for each parameter
for each of these eight patients. Changes in the serum concen-
tration of triglycerides and cholesterol that occurred after
variation in dietary composition were similarly correlated to the
changes in the rate of albumin synthesis, urinary albumin
excretion and serum albumin concentration.
Family histories were obtained from each patient to deter-
mine whether there was any reason to suspect the presence of
underlying abnormalities in lipid metabolism in any patient that
might be unrelated to the nephrotic syndrome. Since these
histories were negative, no changes in statistical evaluation
based upon a known family history of deranged lipid metabo-
lism was necessary. Diabetes mellitus might also potentially
cause a change in serum triglyceride concentration indepen-
dently of the effect of the nephrotic syndrome. For this reason,
data were analyzed once using all data points from all patients,
and a second time omitting the diabetic patients to determine
whether exclusion of the diabetic patients gave different statis-
tical results. Results are presented as mean SEM.
Results
Patients clinical characteristics, laboratory values, parame-
ters of albumin homeostasis and dietary caloric and protein
intake appear in Table 1.
The rate of albumin synthesis measured while patients were
consuming a low protein diet (<1 glkglday) was 12.61 1.20
g/l .73 m2/day, and when measured during consumption of a
higher protein diet (>lg/kg/day) was 17.60 1.25 g/l.73
m2/day. The rate of albumin catabolism was 6.61 0.89 g/l.73
m2/day during consumption of the low protein diets and was
9.12 0.78 g/l.73 m2/day during consumption of the higher
protein diets. The rate of albumin synthesis during consumption
of the low protein diet was within the normal range reported by
us [231 (13.80 0.77) and the rate of albumin catabolism during
consumption of either diet was below the normal range reported
by us and by other investigators [23, 16]. Both serum triglycer-
ide and cholesterol concentrations were markedly elevated,
regardless of dietary protein content. Triglycerides were 265
65 mg/dl for the nine measurements made on patients eating a
diet with a protein content of <1 g/kg/day, and cholesterol was
325 44 mg/dl. Triglycerides were 306 75 mg/dl when
measured during consumption of a diet with a protein content
of >1 glkglday, and cholesterol was 376 55 mg/dl. From these
data it was clear that neither serum cholesterol nor triglyceride
concentration were elevated as a result of an absolute increase
in the rate of albumin synthesis in these patients as a group. It
was still possible however, that the relative rate of albumin
synthesis was responsible for variations of serum lipid concen-
trations within the nephrotic patient population.
Urinary albumin excretion was dependent both upon the rate
of albumin synthesis, with a partial correlation coefficient of
0.8226, P < 0.001 and upon renal albumin clearance, with a
partial correlation coefficient of 0.8584 P <0.0005, but not upon
serum albumin concentration. The r value for the multiple
regression was 0.9231, r2 = 0.8521. The relationship was
unchanged by omission of the diabetic patients and was not
influenced by degree of renal insufficiency or by patient age.
Thus, the rate of urinary albumin excretion is not itself an
independent variable, but is instead a function of two indepen-
dent processes: 1.) the change in glomenilar permselectivity
that is the primary process responsible for loss of macromol-
ecules in the urine, and is most appropriately expressed as the
renal clearance of albumin, or some other macromolecule; and
2.) the ability of the liver to increase the rate of albumin
synthesis sufficiently to stabilize serum—albumin concentration
in the presence of external loss; that is to re-establish a steady
state in the presence of the increased renal clearance of
macromolecules.
The rate of albumin synthesis was dependent only upon
urinary albumin excretion with a partial correlation of 0.9492, P
<0.0001, and not upon either serum colloid osmotic pressure or
serum albumin concentration. The linear relationship between
the rate of albumin synthesis and urinary albumin excretion is
shown in Figure 1.
Serum cholesterol concentration was dependent upon the
renal clearance of albumin with a partial correlation coefficient
of 0.8920, r2 = 0.7957, P <0.0001 and upon serum albumin
concentration, with a partial correlation coefficient of 0.7988, r2
= 0.6381, P = 0.025. Residual r2 added to the regression by
albumin synthesis rate was essentially zero. The dependence of
serum cholesterol concentration on the renal clearance of
albumin, and the independence of serum cholesterol concentra-
1372 Kaysen et a!
27 A
I
25
23
21
19
17
15
13
11
9
.S
. .
.
.
• $
.
900
800
700
600
500
400
300
200
100
0
E
0
a
aa0
U
E
a(I)
r = 0.823
P 0.0001
8.906 + .9492 * X
2 4 6 8 10 12 14 16
r=0.839S. P = 0.0001
. 239.9 + .3013 X
0
Urinary albumin excretion, g/1.73 m2/day
Fig. 1. Correlation between the rate of albumin synthesis and average
urinary albumin excretion in nephroiic patients.
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Fig. 2. Correlation between serum cholesterol concentration and the
renal clearance of albumin (A) and serum albumin concentration (B) in
nephrotic patients.
tion on the rate of albumin synthesis, remained even when data
obtained from the diabetic patients were removed from the
analysis.
It should be noted that serum cholesterol concentration
correlated positively with the rate of albumin synthesis r =
0.528, P < 0.02, serum colloid osmotic pressure r = 0.662, P <
0.002, and with urinary albumin excretion r = 0.741, P <
0.0005, as well as with the renal clearance of albumin r = 0.892,
P < 0.0001 (Fig. 2A), and with serum albumin concentration r
= 0.799 P < 0.0001 (Fig. 2B) when analyzed by univariant
analysis, but the contribution of the first three parameters to
serum cholesterol concentration were found to either be insig-
nificant or not independent by multivariant analysis.
Changes in serum cholesterol concentration ( Chol) result-
ing from changes in dietary composition were dependent only
upon changes in renal albumin clearance ( Albclear) by
multiple regression analysis, with a partial correlation coeffi-
cient of 0.9259, P < 0.001), but not upon changes in serum
albumin concentration ( SAIb), changes in colloid osmotic
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Renal albumin clearance, ,uI/min
Fig. 3. Correlation between serum triglyceride concentration and the
renal clearance of albumin in nephrotic patients,
pressure (COP), or changes in the rate of albumin synthesis (
AibSyn). These relationships remained unchanged whether
data obtained from all patients were analyzed or whether data
from the three patients with diabetic nephropathy, or data from
any other individual patient were removed from the array.
Serum triglyceride concentration was dependent both upon
the renal clearance of albumin, with a partial correlation coef-
ficient of 0.8142, r2 = 0.6629, P < 0.0001, and the rate of
albumin synthesis, with a partial correlation coefficient of
0.3340, r2 = 0.1116, P 0.028, but not upon serum albumin
concentration, colloid osmotic pressure, or upon any other
parameter tested. This relationship was not changed by removal
of the data from the three patients with diabetic renal disease.
The linear relationship between serum triglyceride concentra-
tion and the renal clearance of albumin is shown in Figure 3.
When changes in serum triglycerides ( Trig) that occurred
subsequent to the alteration in dietary composition were ana-
lyzed by multiple regression analysis, Trig was found to be
dependent upon Li AlbSyn, with a partial correlation coefficient
of 0.790, P < 0.002, (the linear relationship between these
variables is demonstrated in Fig. 4A) and upon SAlb, P <
0.004 (Fig. 4B) with a combined r2 of 0.929, P < 0.001. These
relationships were not dependent upon inclusion of the data
obtained from the diabetic patients.
Discussion
The primary pathologic process that occurs in the nephrotic
syndrome is a change in the permselectivity of the glomerular
basement membrane allowing the passage into the urine of
macromolecules that are normally excluded from glomerular
ultrafiltrate [31]. Other processes that occur should result from
that loss or from the homeostatic responses to it. In order to
determine what relationship, if any, the various interdependent
processes may have on serum lipid concentration, it is neces-
sary to examine the relationship between them in order to
elucidate what indeed are dependent and what are independent
variables.
The relationship between urinary albumin excretion, and the
rate of albumin synthesis is more than a casual one. After an
=0.821P= 0.01250.08 + 20.06 X
—260
—0.05 0.05 0.15 0.25 0.35 0.45
Serum albumin, gidI
Fig. 4. Correlation between changes in serum triglyceride concentra-
tion ( Trig) and changes in albumin synthesis rate (i ALB SYN) (A)
and changes in serum albumin concentration that resulted from alter-
ation in dietary protein intake.
increase in the renal clearance of albumin, plasma albumin
concentration and total albumin pools will decrease if net
albumin availability resulting from increased synthesis, de-
creased catabolism or both does not occur. The ultimate result
of an increase in the renal clearance of albumin would then be
a decrease in albumin pools and plasma concentration with no
steady state increase in albuminuria. It is not surprising, there-
fore, that there is a close correlation between the magnitude of
albuminuria and the rate of albumin synthesis. It may not be
useful to consider urinary albumin excretion as an independent
variable, but instead as a function of two other clearly indepen-
dent variables: the rate of albumin synthesis and the renal
clearance of albumin.
The serum concentrations of cholesterol and triglycerides
were each increased, both correlated with urinary albumin
excretion and with the renal clearance of albumin. Serum
cholesterol concentration was entirely independent of the rate
of albumin synthesis by multivariant analysis, and both the
absolute value of serum cholesterol as well as Chol correlated
700
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with the renal clearance of albumin or changes in its renal
clearance, respectively, and not with the rate of albumin
synthesis. These relationships were not dependent upon the
inclusion or exclusion of any individual patient, nor were they
dependent upon patient age, degree of renal impairment nor
upon the presence or absence of diabetes mellitus.
The rate of albumin synthesis was increased only modestly
for the group of patients studied, even considering only those
measurements performed on patients eating a high protein diet.
Albumin synthesis was within the normal range, or reduced for
patients consuming a low protein diet. Despite this, the serum
concentration of both cholesterol and triglycerides was in-
creased in patients eating either diet. An increase in the
absolute rate of albumin synthesis is therefore not directly
linked to the derangement in lipid metabolism, and the lack of
correlation between serum cholesterol concentration and the
rate of albumin synthesis within this group of patients further
excludes a direct relationship between hypercholesterolemia
and increased albumin synthesis in nephrotic patients. The rate
of albumin catabolism was reduced significantly compared to
studies in normal populations [16, 19], thus reduction in the rate
of albumin catabolism played a major role in adaption to the
urinary loss of the protein, and allowed these nephrotic patients
to maintain albumin steady state, albeit at a reduced albumin
mass, without a substantial increase in the rate of albumin
synthesis.
Serum triglyceride concentration, like that of cholesterol,
was dependent partly upon the renal clearance of albumin (Fig.
3), but unlike the case of cholesterol, serum triglyceride con-
centration and variations in serum triglyceride concentration (
Trig) were also dependent, at least in part, upon the relative rate
of albumin synthesis within the nephrotic patient population
studied.
McKenzie and Nestle [2] found that patients with the highest
serum triglyceride—concentration had both the greatest urinary
albumin—excretion and the most rapid triglyceride turnover.
Although these investigators measured neither the rate of
albumin synthesis nor the renal clearance of albumin in their
patients, it is reasonable to assume that within their patient
population, albumin synthetic rate was greatest in their most
albuminuric patients, as we have found, and that the rate of
both albumin synthesis and the serum triglyceride concentra-
tion increased in direct proportion. Since they did not directly
measure the rate of albumin turnover, it is not possible to
determine the quantitative relationship between the rate of
albumin synthesis and the rate of triglyceride turnover in their
patients.
It has been suggested that increases in the rate of albumin
synthesis leads to an increase in the synthesis rates of other
hepatic secretory proteins [7, 14, 15]. The synthesis of
lipoproteins and of albumin are both increased in the isolated
perfused livers from nephrotic rats [32]. Early, et al [33]
proposed that, because the rate of albumin synthesis was
increased in nephrosis, the synthesis of all proteins that are
secreted by the liver were also increased because they shared a
common pathway for both synthesis and secretion. Most evi-
dence however would support the hypothesis that the
hepatocyte does not regulate protein secretion [34], but that
regulation of release of secreted proteins is at the level of
synthesis. The observation that, once synthesized, these pro-
teins share a common pathway for secretion does not clarify the
regulation of synthesis of these proteins. The relative rate of
albumin synthesis and the concentration of serum triglycerides
are only weakly related to one another, but it may be possible
that when the rate of albumin synthesis is increased in
nephrosis so is that of apolipoproteins. However, the synthesis
of apolipoproteins may not be the limiting factor in very
low—density lipoprotein (VLDL) production. Any model of
hyperlipemia in nephrosis must also be consistent with the fact
that the rate of albumin synthesis is increased only modestly if
at all in nephrotic patients as a group, while serum lipid
concentration remains markedly elevated. The absolute rate of
albumin synthesis then is probably not directly linked to the
increase in serum triglyceride concentration; however within
the nephrotic patient population, serum triglyceride concentra-
tion increases in direct proportion to the rate of albumin
synthesis. The mechanism for this apparent linkage remains
obscure. It is clear however, that it is the renal loss of albumin
and/or other macromolecules, and not an increase in albumin
synthesis which is central to the nephrotic syndrome.
It is curious that a close correlation exists between the renal
clearance of albumin and the concentration of serum lipids in
these patients. A clue to the interaction between these param-
eters may be found by examining the interrelationship between
the urinary loss of glycoproteins and lipid metabolism. Since
proteins are not only filtered by the glomerulus, but are reab-
sorbed by the renal tubules, the renal clearance of proteins is
usually not useful as an indicator of changes in the glomerular
filtration of macromolecules [35]. Micropuncture studies in
nephrotic rats [36, 37], however, show that under conditions of
nephrotic range proteinuria nearly all albumin filtered at the
glomerulus is excreted in the urine. Similarly [38], the fractional
renal clearance of albumin in nephrotic patients closely corre-
lates with changes in the glomerular permselectivity for, and the
renal clearance of, other macromolecules. It is therefore prob-
able that the glomerular changes in permselectivity that are
expressed here as changes in the renal clearance of albumin
may lead to changes in the renal clearance of other macromol-
ecules whose loss parallels the loss of albumin and influences
lipid metabolism. Results with nephrotic patients have shown
that urinary loss of a1-acid glycoprotein parallels urinary loss of
albumin [39]. This is undoubtedly true for other glycoproteins
as well.
Several workers have shown that as the nephrotic syndrome
becomes more severe, VLDL (and chylomicrons, CM) and
intermediate density lipoproteins, (IDL) increase and low den-
sity lipoproteins (LDL) decline [12]. Gherardi, Vecchia and
Calandra [40] have shown that the major very—low-density
lipoprotein in nephrotic rats closely resembled IDL. These
observations taken together suggest a defect in the interaction
of VLDL (and chylomicrons) with lipoprotein lipase as well as
a defect in the hepatic metabolism of VLDL remnants and
chylomicron remnants. This latter defect could interfere with
the function of remnant particles (RM) as negative feedback
signals to limit cholesterol and triglyceride synthesis by the
liver [39, 41, 42] leading to an accelerated synthesis of VLDL
lipids and secretion of VLDL.
Other cofactors may be involved in these metabolic blocks.
Staprans and Felts [6] demonstrated that nephrotic
hyperlipemia in the rat is characterized by a decreased clear-
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ance of injected triglyceride. They found that the a1- acid
glycoprotein (aAG) fraction isolated from human nephrotic
urine could stimulate the lipoprotein lipase reaction in vitro,
and promptly corrected the triglyceride removal defect when
injected into nephrotic rats [6]. The active component in the
urinary aAG fraction was identified as heparan sulfate [43, 44].
Heparan sulfate is also present in human plasma [45]. It was
further established that nephrotic patients excrete far less
heparan sulfate than control subjects [44]. These findings sug-
gest that some factor lost in urine of nephrotic patients influ-
ences the synthesis of heparan sulfate which, in turn, may
influence the metabolism of CM, VLDL and possibly remnants
leading to the observed altered lipoprotein pattern. Thus, these
data suggest that the loss of macromolecules, in parallel with
albumin, from the plasma into urine may be causally related to
the hyperlipemia of the nephrotic syndrome.
Hyperlipemia in nephrosis is a complex phenomenon involv-
ing both increased synthesis of lipoproteins by the liver [3, 4,
7—9] as well as a decrease in their catabolic rate [2—6, 4]. Its
occurrence in the nephrotic syndrome may be the result of the
urinary loss of macromolecules involved in the initial catabolic
reactions involved in the clearance of both chylomicrons and
hepatic VLDL. The renal clearance of these macromolecules
may parallel the renal clearance of albumin. Although serum
triglyceride concentration tends to parallel the rate of albumin
synthesis in this nephrotic patient population, the observation
that the absolute rate of albumin synthesis is only slightly
elevated makes a direct causal link between these processes
questionable.
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